Patents by Inventor Camilo QUEVEDO

Camilo QUEVEDO has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds
    Patent number: 12024506
    Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: July 2, 2024
    Assignee: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
    Inventors: Terrence Rabbitts, Camilo Quevedo, Abimael Cruz, Simon Phillips, Philip Spencer Fallon, Jonathan Neil Dunn, Joshua Robert Freem, Lydia Yuen-Wah Lee, Tenin Traore, Sophie Caroline Williams
  • Compounds useful in the treatment of disorders associated with mutant RAS
    Patent number: 11970469
    Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
    Type: Grant
    Filed: June 3, 2019
    Date of Patent: April 30, 2024
    Assignee: THE INSTITUTE OF CANCER RESEARCH: ROYAL CANCER HOSPITAL
    Inventors: Terrence Rabbitts, Camilo Quevedo, Carole Bataille
  • Inhibitors of RAS-effector protein interactions
    Patent number: 11724999
    Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
    Type: Grant
    Filed: January 23, 2019
    Date of Patent: August 15, 2023
    Assignee: OXFORD UNIVERSITY INNOVATION LIMITED
    Inventors: Terrence Rabbitts, Camilo Quevedo, Abimael Cruz, Simon Phillips, Philip Spencer Fallon, Anna Hopkins, Lydia Yuen-Wah Lee, Tenin Traore, Sophie Caroline Williams, Natalie Louise Winfield
  • COMPOUNDS USEFUL IN THE TREATMENT OF DISORDERS ASSOCIATED WITH MUTANT RAS
    Publication number: 20210214322
    Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
    Type: Application
    Filed: June 3, 2019
    Publication date: July 15, 2021
    Inventors: Terrence RABBITTS, Camilo QUEVEDO, Carole BATAILLE
  • INHIBITORS OF RAS-EFFECTOR PROTEIN INTERACTIONS
    Publication number: 20210047305
    Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
    Type: Application
    Filed: January 23, 2019
    Publication date: February 18, 2021
    Inventors: Terrence RABBITTS, Camilo QUEVEDO, Abimael CRUZ, Simon PHILIPS, Philip Spencer FALLON, Anna HOPKINS, Lydia Yuen-Wah LEE, Tenin TRAORE, Sophie Caroline WILLIAMS, Natalie Louise WINFIELD
  • COMPOUNDS
    Publication number: 20210009576
    Abstract: The present invention relates to compounds of Formula I as defined herein, and salts and solvates thereof. (I) The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to compounds of Formula (I) for use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions in which inhibition of a RAS-effector protein-protein interaction is implicated.
    Type: Application
    Filed: January 23, 2019
    Publication date: January 14, 2021
    Inventors: Terrence RABBITTS, Camilo QUEVEDO, Abimael CRUZ, Simon PHILLIPS, Philip Spencer FALLON, Jonathan Neil DUNN, Joshua Robert FREEM, Lydia Yuen-Wah LEE, Tenin TRAORE, Sophie Caroline WILLIAMS